Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Glioma Malignancy-Dependent NDRG2 Gene Methylation and Downregulation Correlates with Poor Patient Outcome.

Skiriutė D, Steponaitis G, Vaitkienė P, Mikučiūnas M, Skauminas K, Tamašauskas A, Kazlauskas A.

J Cancer. 2014 May 13;5(6):446-56. doi: 10.7150/jca.9140. eCollection 2014.

2.

Promoter methylation of AREG, HOXA11, hMLH1, NDRG2, NPTX2 and Tes genes in glioblastoma.

Skiriutė D, Vaitkienė P, Ašmonienė V, Steponaitis G, Deltuva VP, Tamašauskas A.

J Neurooncol. 2013 Jul;113(3):441-9. doi: 10.1007/s11060-013-1133-3. Epub 2013 Apr 28.

PMID:
23624749
3.

GATA4 and DcR1 methylation in glioblastomas.

Vaitkienė P, Skiriutė D, Skauminas K, Tamašauskas A.

Diagn Pathol. 2013 Jan 15;8:7. doi: 10.1186/1746-1596-8-7.

4.

Associations between TFPI-2 methylation and poor prognosis in glioblastomas.

Vaitkienė P, Skiriutė D, Skauminas K, Tamašauskas A.

Medicina (Kaunas). 2012;48(7):345-9.

5.

MGMT, GATA6, CD81, DR4, and CASP8 gene promoter methylation in glioblastoma.

Skiriute D, Vaitkiene P, Saferis V, Asmoniene V, Skauminas K, Deltuva VP, Tamasauskas A.

BMC Cancer. 2012 Jun 6;12:218. doi: 10.1186/1471-2407-12-218.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk